The American Journal of Medicine
Volume 121, Issue 10 , Pages 868-869 , October 2008

Synchronicity

  • Matthew Mattern, MD

      Affiliations

    • Department of Nuclear Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC
    • ,
  • Perry S. Gerard, MD

      Affiliations

    • Division of Nuclear Medicine, Maimonides Medical Center, Brooklyn, NY
    • Corresponding Author InformationRequests for reprints should be addressed to Perry S. Gerard, MD, Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219
    • ,
  • Matthew D. Geller, DO

      Affiliations

    • Division of Nuclear Medicine, Maimonides Medical Center, Brooklyn, NY

References 

  1. Hofman MS, Constantinidou A, Acland K, et al. Melanoma Group Assessing response to chemotherapy in metastatic melanoma with FDG PET: early experience. Nucl Med Commun. 2007;28:902–906
  2. Pleiss C, Risse JH, Biersack HJ, Bender H. Role of FDG-PET in the assessment of survival prognosis in melanoma. Cancer Biother Radiopharm. 2007;22:740–747
  3. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–579
  4. Kufe DW, Pollock RE, Weichselbaum RR. Holland-Frei Cancer Medicine. 6th ed.. Hamilton, Ontario: BC Decker; 2003;
  5. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25
  6. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20–37
  7. Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: A multinational record linkage study. J Clin Endocrinol Metab. 2006;91:1819–1825
  8. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol. 2006;163:521–527
  9. Choi JY, Lee KS, Kwon OJ, et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23:7654–7659
  10. van Westreenen HL, Westerterp M, Jager PL, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005;46:1321–1325
  11. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res. 2007;5:87–90
  12. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648

 Michael Bettmann, MD, Section Editor

PII: S0002-9343(08)00759-6

doi: 10.1016/j.amjmed.2008.08.002

The American Journal of Medicine
Volume 121, Issue 10 , Pages 868-869 , October 2008

Article Tools

* Image Usage & Resolution